Cb Therapeutics, Inc.

Tyrone Jacob Yacoub

James Wade

Jacob Michael Vogan

Kirsten Tang

Rachel Nadine Burnett

Laura Flatauer Peiffer

The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.

Biosynthetic production of psilocybin and related intermediates in recombinant organisms

The methods and system disclose an automated pipeline which receives a list of Accession IDs corresponding to transcriptomic, proteomic, genomic, or metabolomic data. Each Accession ID is submitted in parallel, launching a specific cloud computer to carry out a customized, fully automated transcriptome assembly (or proteomic assembly or genome assembly or metabolome assembly) and analysis by the automated pipeline. The output from multiple assemblies is automatically compiled and compared with genes of interest to identify new gene variants. The new gene variants can be used as queries by the automated pipeline to: discover variants of the variants; and determine new studies to analyze.

Growing community of inventors

San Diego, CA, United States of America

Tyrone Jacob Yacoub